GlassScriptPhysician profile
Lawrence J Leventhal
NPI 1174521165
$1,105,411.90
in general payments reported to CMS, 2019-2025
23 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397K · 2020: $133K · 2021: $155K · 2022: $163K · 2023: $144K · 2024: $72K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $227K · Travel and Lodging: $26K · Food and Beverage: $4,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $226,750.00 |
| Travel and Lodging | $26,240.13 |
| Food and Beverage | $4,627.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $334,012.51 | 2019-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $317,272.44 | 2019-2024 | Taltz |
| Abbvie INC. | $224,205.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $72,556.23 | 2019-2023 | |
| Celgene Corporation | $61,797.06 | 2019 | |
| Ucb, INC. | $40,050.73 | 2019-2023 | Cimzia |
| Genzyme Corporation | $28,992.90 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $14,474.27 | 2019-2021 | |
| Pfizer INC. | $5,965.29 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $3,861.84 | 2019 | |
| Janssen Research & Development, LLC | $1,317.37 | 2025 | |
| Mallinckrodt Hospital Products INC. | $246.50 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $158.35 | 2019 | |
| Glaxosmithkline, LLC. | $149.81 | 2019 | |
| Pacira Therapeutics, INC. | $88.80 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $76.10 | 2019 | |
| Genentech USA, INC. | $55.97 | 2019-2020 | |
| Radius Health, INC. | $40.98 | 2019 | |
| Hikma Pharmaceuticals USA | $25.65 | 2019 | |
| Medexus Pharma, INC. | $24.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $14.78 | 2021 | |
| Janssen Biotech, INC. | $12.16 | 2019 | |
| Horizon Therapeutics Plc | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.